RPG Life Sciences is expanding its pharmaceutical business with a new acquisition. Its wholly owned subsidiary, RPG Active Pharma Ltd, has agreed to buy the Active Pharmaceutical Ingredients business of Raghava Life Sciences for up to ₹135 crore.
The deal will be completed through a slump sale, which means RPG Active Pharma will take over the business and its assets rather than buying the entire company. The deal still needs approval from the government and authorities before it can be finalised.
The acquisition will add a 300-KL manufacturing facility near Hyderabad to RPG Active Pharma’s operations. The plant has EU-GMP and WHO-GMP approvals and also includes a research and development facility. Raghava’s business includes 29 API molecules, including 22 already commercialised products and seven products under development. These products are used in areas such as diabetes, cardiovascular diseases and CNS-related treatments. The business reported revenue of around ₹19 crore in FY26.
This is RPG Active Pharma’s Second major acquisition, following its recent purchase of Active Generic. The company said the move will help expand its manufacturing capacity, product range and reach in the growing API market.
RPG Life Sciences Managing Director Ashok Nair said the company plans to combine Raghava’s manufacturing and product strengths with Actis’ intermediate capabilities to build a stronger API business. The acquisition will be funded through RPG Active Pharma’s recent equity raise.
